Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.

Although contralateral retinal changes have been described for many other vascular endothelial growth factor inhibitors, there is little evidence for brolucizumab. We describe a repeated dose- and time-related effect on the uninjected eye in a case of nAMD.